DrugPatentWatch Database Preview
Array Biopharma Inc Company Profile
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the competitive landscape for ARRAY BIOPHARMA INC, and what generic alternatives to ARRAY BIOPHARMA INC drugs are available?
ARRAY BIOPHARMA INC has two approved drugs.
There are eighteen US patents protecting ARRAY BIOPHARMA INC drugs.
There are two hundred and thirty-eight patent family members on ARRAY BIOPHARMA INC drugs in fifty-two countries and nineteen supplementary protection certificates in seven countries.
Summary for Array Biopharma Inc
| International Patents: | 238 |
| US Patents: | 18 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Array Biopharma Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Array Biopharma Inc | BRAFTOVI | encorafenib | CAPSULE;ORAL | 210496-002 | Jun 27, 2018 | RX | Yes | Yes | 9,850,229 | Start Trial | Start Trial | ||||
| Array Biopharma Inc | MEKTOVI | binimetinib | TABLET;ORAL | 210498-001 | Jun 27, 2018 | RX | Yes | Yes | 10,005,761 | Start Trial | Start Trial | ||||
| Array Biopharma Inc | BRAFTOVI | encorafenib | CAPSULE;ORAL | 210496-001 | Jun 27, 2018 | DISCN | Yes | No | Start Trial | Start Trial | |||||
| Array Biopharma Inc | BRAFTOVI | encorafenib | CAPSULE;ORAL | 210496-002 | Jun 27, 2018 | RX | Yes | Yes | 8,501,758 | Start Trial | Y | Y | Start Trial | ||
| Array Biopharma Inc | BRAFTOVI | encorafenib | CAPSULE;ORAL | 210496-001 | Jun 27, 2018 | DISCN | Yes | No | 8,946,250 | Start Trial | Y | Y | Start Trial | ||
| Array Biopharma Inc | MEKTOVI | binimetinib | TABLET;ORAL | 210498-001 | Jun 27, 2018 | RX | Yes | Yes | 8,193,229 | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Array Biopharma Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Denmark | 2130537 | Start Trial |
| European Patent Office | 2782557 | Start Trial |
| Eurasian Patent Organization | 025222 | Start Trial |
| Israel | 204419 | Start Trial |
| Cyprus | 1116783 | Start Trial |
| Russian Federation | 2006109600 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Array Biopharma Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2470526 | C20190011 00282 | Estonia | Start Trial | PRODUCT NAME: ENKORAFENIIB;REG NO/DATE: EU/1/18/1314 24.09.2018 |
| 2727918 | 2019C/509 | Belgium | Start Trial | PRODUCT NAME: COMBINAISON DE BINIMETINIB ET D'ENCORAFENIB, CHACUN SOUS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/18/1315 ET EU/1/18/1314 20180924 |
| 2470526 | CA 2019 00012 | Denmark | Start Trial | PRODUCT NAME: ENCORAFENIB I ALLE FORMER BESKYTTET AF GRUNDPATENTET; REG. NO/DATE: EU/1/18/1314 20180924 |
| 2470526 | PA2019005 | Lithuania | Start Trial | PRODUCT NAME: ENKORAFENIBAS BET KOKIOMIS FORMOMIS, KURIOMS TAIKOMA PAGRINDINIO PATENTO APSAUGA; REGISTRATION NO/DATE: EU/1/18/1314 20180920 |
| 1482932 | CA 2019 00011 | Denmark | Start Trial | PRODUCT NAME: BINIMETINIB I ALLE FORMER BESKYTTET AF GRUNDPATENTET; REG. NO/DATE: EU/1/18/1315 20180924 |
| 1482932 | LUC00100 | Luxembourg | Start Trial | PRODUCT NAME: MEKTOVI - BINIMETINIB; AUTHORISATION NUMBER AND DATE: EU/1/18/1315 20180924 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
